Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of GPO-Hep C vs EPCLUSA under Fasting Conditions
TCTR20200224005Phase 1Not yet recruiting
- Sponsor
- Government Pharmaceutical Organization
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sofosbuvir + velpatasvir in chronic hepatitis C (CHC) (2 arms), sponsored by Government Pharmaceutical Organization. Primary endpoint: Bioequivalence of GPO-Hep C vs EPCLUSA. Planned start May 2020; status: not yet recruiting.
02
Drugs
sofosbuvir + velpatasvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on TCTR20200224005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200224005.